Interferon β-1a reduces increased interleukin-16 levels in multiple sclerosis patients

Acta Neurologica Scandinavica

Volumn 130, Issue 1, 2014, Pages 46-52

  Nischwitz, S ^a   Faber, H ^a   Samann P G ^a   Domingues, H S ^b,c   Krishnamoorthy, G ^b   Knop, M ^a   Muller Sarnowski F ^a   Yassouridis, A ^a   Weber, F ^a  

^a MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

^b MAX PLANCK INSTITUTE OF NEUROBIOLOGY   (Germany)

^c UNIVERSITY OF PORTO   (Portugal)

Author keywords

Experimental autoimmune encephalomyelitis; Interferon ; Interleukin 16; Multiple sclerosis; Th17 cells; Treatment

Indexed keywords

BETA1A INTERFERON; BIOLOGICAL MARKER; CD4 ANTIGEN; CHEMOATTRACTANT; INTERLEUKIN 16; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; BETA INTERFERON; IMMUNOLOGIC FACTOR;

ADULT; ANIMAL CELL; ARTICLE; AUTOIMMUNITY; BLOOD LEVEL; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DRUG DOSE INCREASE; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNOCOMPETENT CELL; IN VITRO STUDY; MALE; MOUSE; MULTIPLE SCLEROSIS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOGENESIS; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; T LYMPHOCYTE SUBPOPULATION; TH1 CELL; TH17 CELL; TRANSGENIC MOUSE; ANIMAL; BIOSYNTHESIS; BLOOD; C57BL MOUSE; IMMUNOLOGY; METABOLISM; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; YOUNG ADULT;

ADULT; ANIMALS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; INTERFERON-BETA; INTERLEUKIN-16; MAGNETIC RESONANCE IMAGING; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; REAL-TIME POLYMERASE CHAIN REACTION; TH1 CELLS; TH17 CELLS; YOUNG ADULT;

EID: 84902120155     PISSN: 00016314     EISSN: 16000404     Source Type: Journal    
DOI: 10.1111/ane.12215     Document Type: Article

References (29)

1. Compston A, Coles A. Multiple sclerosis. Lancet 2008;372:1502-17.
2. van der Valk P, de Groot CJA. Staging of multiple sclerosis (MS) lesions: pathology of the time frame of MS. Neuropathol Appl Neurobiol 2000;26:2-10.
3. Cruikshank WW, Kornfeld H, Center MC. Interleukin- 16. J Leukoc Biol 2000;67:757-66.
4. + T-cells is activation dependent. J Immunol 1999;162:1287-93.
5. Glass WG, Sarisky T, Vecchio AM. Not-so-sweet sixteen: the role of IL-16 in infectious and immune-mediated inflammatory diseases. J Interferon Cytokine Res 2006;26:511-20.
6. + lymphocytes and monocytes. J Immunol 1987;138:3817-23.
7. + T-cell infiltration and improves paralysis and histopathology of relapsing EAE. J Neurosci Res 2005;79:680-93.
8. Skundric DS, Zhou W, Cruikshank WW, Dai R. Increased levels of bioactive IL-16 correlate with disease activity during relapsing experimental autoimmune encephalomyelitis (EAE). J Autoimmun 2005;25:206-14.
9. + Th1 inflammation and phosphorylation of axonal cytoskeleton in multiple sclerosis lesions. J Neuroinflammation 2006;26:3-13.
10. Clerico M, Contessa G, Durelli L. Interferon-beta1a for the treatment of multiple sclerosis. Expert Opin Biol Ther 2007;7:535-42.
11. Reske D, Thomas AV, Petereit HF, Fink GR, Schroeter M. Impact of immunomodulatory treatment on leukocyte cytokine production in multiple sclerosis patients and healthy donors. NeuroImmunoModulation 2009;16:385-91.
12. Annibali V, di Giovanni S, Cannoni S et al. Gene expression profiles reveal homeostatic dynamics during interferon-beta therapy in multiple sclerosis. Autoimmunity 2007;40:16-22.
13. Jana M, Pahan K. IL-12 p40 homodimer, but not IL-12 p70, induces the expression of Il-16 in microglia and macrophages. Mol Immunol 2008;46:773-83.
14. Cua DJ, Sherlock J, Chen Y et al. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 2003;421:744-8.
15. Langrish CL, Chen Y, Blumenschein WM et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med 2005;201:233-40.
16. Axtell RC, de Jong BA, Boniface K et al. T helper type 1 and 17 cells determine efficacy of interferon-beta in multiple sclerosis and experimental encephalomyelitis. Nat Med 2010;16:406-12.
17. Betelli E, Pagany M, Weiner HL, Linington C, Sobel RA, Kuchroo VK. Myelin oligodendrocyte glycoprotein-specific T cell receptor transgenic mice develop spontaneous autoimmune optic neuritis. J Exp Med 2003;197:1073-81.
18. Krishnamoorthy G, Lassmann H, Wekerle H, Holz A. Spontaneous opticospinal encephalomyelitis in a double-transgenic mouse model of autoimmune T cell/B cell cooperation. J Clin Invest 2006;116:2385-92.
19. Domingues HS, Mues M, Lassmann H, Wekerle H, Krishnamoorthy G. Functional and pathogenic differences of Th1 and Th17 cells in experimental autoimmune encephalomyelitis. PLoS ONE 2010;5:e15531.
20. + T cell ratio and T cell activation in multiple myeloma: reference to IL-16. Leuk Res 2002;26:705-11.
21. Rentzos M, Rombos A. The role of IL-15 in central nervous system disorders. Acta Neurol Scand 2012;125:77-82.
22. Mathy NL, Scheuer W, Lanzendoerfer M et al. Interleukin-16 stimulates the expression and production of pro-inflammatory cytokines by human monocytes. Immunology 2000;100:63-9.
23. Suzuki T, Ishiguro A, Shimbo T. Transient elevation of interleukin-16 levels at the initial stage of meningitis in children. Clin Exp Immunol 2003;131:484-9.
24. Liu C, Mills J, Dixon K et al. IL-16 signalling specifically induces STAT6 activation through CD4. Cytokine 2007;38:145-50.
25. Stromnes IM, Cerretti LM, Liggitt D, Harris RA, Goverman JM. Differential regulation of central nervous system autoimmunity by T(H)1 and T(H)17 cells. Nat Med 2008;14:337-42.
26. Lynch EA, Heijens CAW, Horst NF, Center DM, Cruikshank WW. Cutting edge: Il-16/CD4 preferentially induces Th1 cell migration: requirement of CCR5. J Immunol 2003;171:4965-8.
27. Durelli L, Conti L, Clerico M et al. T-helper 17 cells expand in multiple sclerosis and are inhibited by interferon-beta. Ann Neurol 2009;65:499-509.
28. Kvarnström M, Ydrefors J, Ekerfelt C, Vrethem M, Ernerudh J. Longitudinal interferon-β effects in multiple sclerosis: differential regulation of IL-10 and IL-17A, while no sustained effects on IFN-γ, IL-4 or IL-13. J Neurol Sci 2013;325:79-85.
29. Sweeney CM, Lonergan R, Basdeo SA et al. IL-27 mediates the response to IFN-β therapy in multiple sclerosis patients by inhibiting Th17 cells. Brain Behav Immun 2011;25:1170-81.